Resources:

Find resources by:

Sort by:

Date Resource A-Z Random

Resources from the last:

Box size:

Filer text box:

Topic familiarity:

Grid Layout:

Collections that use this topic:

Collection topics:

Adrenal Bone Cardiovascular Diabetes Endocrine-Disrupting Chemicals Endocrine-Related Cancer Metabolism Neuroendocrinology Obesity Reproduction Steroid and Steroidogenesis Thyroid

Diabetes Glucagon

Islets Insulin BetaCells Pancreas Glucose Hyperglycemia Hypoglycemia Insulinoma Glucagon IGF Type 1 Type 2

Congratulations to the awardees of our third round of 2024 grants

Semaglutide approved as obesity treatment in England

Autoinjector is better for dispensing glucagon

Autoinjector is better for dispensing glucagon

Early Career Grants awarded

Early Career Grants awarded

New potential target to help treat diabetes

Lowering sodium uptake in alpha cells may help treat type-2 diabetes

A type-2 diabetes treatment may increase the need for lower limb amputation

Clinical Biochemistry PhD at the University of Cambridge

Nasal glucagon safe for children

Crystal structure of glucagon receptor key for type 2 diabetes drug development

Type 2 diabetes therapy may prevent memory loss

The gut plays a key role in the development of type 2 diabetes

New technique colours biomolecules in tissue

Post-bariatric hypoglycemia prevented through novel glucagon pump

Glucagon receptor antagonist ups blood pressure in type 2 diabetes

Zebrafish as models of mammalian glucagon action

Glucagon receptor inactivation leads to α-cell hyperplasia in zebrafish

GLP-1 may play a major role in reproduction

Stability of GLP-1 and glucagon in human plasma

Next generation of prescription diet pills could increase risk of colon cancer

Glucagonoma-induced acute heart failure

Impact of DPP4 inhibition on incretin effect

GLP1–ANP axis in humans?

PCOS, weight reduction and liraglutide

Multihormone reverses metabolic damage of high calorie diet (Alpha Galileo, 15 January 2014)

Appetite hormone misfires in obese people (EurekAlert, 20 August 2013)

Scripps Research Institute scientists find 3D structure of key drug target for diabetes (AlphaGalileo, 17 July 2013)

Effects of GLP1R agonists on primary thyroid C-cells

Proglucagon sorting in endocrine cells

Fellowship: Development and validation of models of glucagon and amylin action in healthy and type 1 diabetic subjects, Padova, Italy

Most-used diabetes drug works in different way than previously thought (EurekAlert, 6 January 2013)

New findings on glucagon synthesis (EurekAlert, 3 December 2012)

PhD Fellowship in diabetes, Université Catholique de Louvain, Belgium

Plenary lecture 7 'Diabetes as a gut disease' 10:45, Main Hall

Post-doc fellowship, Université Catholique de Louvain, Belgium

Regulation of glucose homeostasis

Research Associate (two positions), University of Cambridge

Postdoctoral fellow, Brussels, Belgium

Simple gut hormone combo makes our brains think we're full (EurekAlert, 25 October 2011)

Simple gut hormone combo makes our brains think we're full (EurekAlert, 25 October 2011)

Post-doctoral position, Université Catholique de Louvain, Belgium

A study on glucagonoma

New drug for diabetics could end ordeal of daily insulin jabs (Daily Mail, 25 January 2010)

The Impact of Subcutaneous Infusions of three Anorexigenic Gut Hormones Glucagon-like Peptide-1, Oxy...

Glucagon-like peptide-1 secretion within the developing human fetus and its role in beta cell develo...

Glucagon Increases Energy Expenditure Independently of Brown Adipose Tissue Activation in Humans

Does glucagon need the brain for its effects on blood glucose?

Does glucagon need the brain for its effects on blood glucose?

Does glucagon need the brain for its effects on blood glucose?

Energy intake following infusion of glucagon and GLP-1: a double-blind crossover study

GLP-1 and glucagon co-secretion due to a pancreatic neuroendocrine tumour causing diabetes and subse...

The use of glucagon for management of severe-persistent hypoglycaemia in patients with congenital hy...

Debate - PRO: Use of Dual Hormone (glucagon) v. single hormone (insulin) in the treatment of diabetes with close-loop system

Debate - CON: Use of Dual Hormone (glucagon) v. single hormone (insulin) in the treatment of diabetes with close-loop system

Pharmacokinetics of Intravenous Glucagon in Children with Hyperinsulinaemic Hypoglycaemia

Expression and localisation of insulin, glucagon, amylin, pancreatic polypeptide and PDX-1 in pancre...

Dasiglucagon safety in paediatric participants with CHI

Are Glucagon-like peptide-1 (GLP-1) receptor agonists a new treatment option for hypothalamic obesity in the paediatric population: Preliminary experience from a tertiary paediatric endocrine centre

Growth Hormone Response to Glucagon Stimulation Test in Transitional Age

Efficacy and Safety across Subgroups in Children with Congenital Hyperinsulinism Treated with Dasiglucagon

Project to Develop BSPED UK Standardised Guidelines for Sex Hormone Priming and Glucagon Stimulation...

Project to Develop BSPED UK Standardised Guidelines for Sex Hormone Priming and Glucagon Stimulation...

Comparison of patient experiences of the glucagon and insulin pituitary provocation tests: time for ...

A gut feeling about glucagon

Glucose-dependent insulinotropic peptide (GIP) stimulates Glucagon-like peptide (GLP)-1 from human a...

Novel glucagon receptor antagonist peptides improve glycaemic control and partially protect against ...

Development of severe gastroparesis and gastric food bezoar following administration of glucagon-like peptide 1-receptor agonist (GLP1-RA) therapy.

Lipid handling by the glucagon family of G protein-coupled receptors

Glucagonomas: diagnostic features and outcomes of first line treatment in a series of 18 patients

Glucagon-like peptide 1 receptor is required for optimal bone strength and quality

Resource not read: Query You and Your Hormones

Prolonged acidosis in SGLT2i-induced euglycaemic diabetic ketoacidosis

How do I ... develop new diabetes drugs by studying natural peptide hormones in patients?

SEX-BASED IMPACT OF PANCREATIC ISLET STRESSORS IN GluCreERT2/Rosa26-eYFP MICE

GENETIC SYNDROMES LINKED TO INSULINOMA AND GLUCAGONOMA

GLP-1 receptor activation and cancer cell chemosensitivity

SEX-SPECIFIC ISLET HORMONE RELEASE BY GHSR1A ANTAGONIST LEAP2

PRECONCEPTION TREATMENT WITH METFORMIN OR EXENATIDE IN PCOS

Mechanisms of β cell dedifferentiation in diabetes

GLP-1R/NPY2R AND REPRODUCTIVE FUNCTION IN MICE FED A HIGH-FAT DIET

A Big Bang in Birmingham! Time for endocrine inspiration

A NEW ERA IN OBESITY MANAGEMENT

OBESITY AND TYPE 2 DIABETES: TIME TO PUT AWAY THE KNIVES?

FAQs (fat accumulation and quality) in non-alcoholic steatohepatitis

Towards self-management in type 1 diabetes

POLYCYSTIC OVARY SYNDROME: THE HUNT FOR NEW THERAPIES

STRESS, TRAUMA AND LATE EFFECTS OF BRAIN TUMOURS

24 hours in the life of a hormone: what time is the right time for a pituitary function test?

GDF15: SOMATIC DISTRESS, APPETITE AND AVERSION

BONE HEALTH AND BARIATRIC SURGERY: SHRINKING BONES?

UNDERSTANDING EARLY-ONSET TYPE 2 DIABETES

SPECIALIST PHARMACISTS IN ENDOCRINOLOGY AN EVOLVING ROLE

Endogenous insulin: its role in the initiation, progression and management of diabetes

Endocrinologist 123 Web

The Endocrinologist Autumn 14 -website.pdf

Endocrinologist 144 Web

Endocrinologist 155 Final File For Online

Endocrinologist 134 Web Updated

Endocrinologist 146 Web

Endocrinologist 153 Web Version

Endocrinologist 129 Web

Endocrinologist 154 Web Version

The Endocrinologist 115 Web FINAL.pdf

Endocrinologist 145 Web

Endocrinologist 150 Web

Endocrinologist 152 Final For Web

The Endocrinologist 117 Web.pdf

Endocrinologist 126

Endocrinologist 128 Web Updated

Endocrinologist 142 Web (1)

Endocrinologist 142 Web

ScreenSummerEndoComplete.pdf

Endocrinologist 135 Web

Endocrinologist 141 Web

GLP-1 and glucagon depict complementary actions on visceral adipose tissue that could mediate metabolic shifts towards catabolism

Glucagon-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a double-blind randomized placebo-controlled study

Evaluation of copeptin levels during glucagon stimulation test in children with suspected growth hormone deficiency

The Relation Between Serum Glucose and Growth Hormone Concentrations During Standard Glucagon Test for GH Release in Short Stature Children

Activation of GPR120 by lipid agonists modulates glucagon secretion in pancreatic islets and improves glucose tolerance in mice

Growth Hormone Response to Glucagon Stimulation Test in Transitional Age

GLP-1RAs and glucagon can reshape adipose differentiation in vitro by activating the browning process

Comparative Study of Glucose Response to Intramuscular Glucagon in Pediatric Growth Hormone Deficiency and Idiopathic Short Stature: What is the risk of hypoglycemia?

The stimulatory effects of glucagon on cortisol and GH secretion occur independently from FGF-21

Novel glucagon receptor antagonist peptides improve glycaemic control and partially protect against streptozotocin induced diabetes in mice

Does the glucagon challenge test add to the utility of a 72 h fast for spontaneous hypoglycemia?

Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus

Comparison of 1 μg ACTH, 250 μg ACTH and glucagon tests for assessment of the hypothalamo-pituitaryadrenal axis in healthy subjects

Cell-cell contact enhances insulin secretion from pancreatic beta-cells but not glucagon secretion from alpha-cells

Evaluation of minutes related to the maximum levels and random basal levels of growth hormone during stimulation test with glucagon

Comparative analysis of the methods for differential diagnosis of non-diabetic hypoglycemia (NDH): Beta-hydroxybutyrate and glucagon test

Expression and Localisation of Insulin, Glucagon, Amylin, Pancreatic Polypeptide and PDX-1 in Pancreatic Tissue of Children with Congenital Hyperinsulinism

Glucagon Response to Hypoglycemia During Extended Oral Glucose Tolerance Test in Children with Cystic Fibrosis and Comparing with Healthy Peers

10.25 A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with T1DM in the home or school setting

Project to develop BSPED UK standardised guidelines for sex hormone priming and glucagon stimulation testing (GST) in children and adolescents

Elimination of fall in glucose during glucagon stimulation test does not completely abolish an increase in growth hormone and cortisol concentrations

Pharmacogenomics and efficacy outcome of therapy with glucagon-like peptide-1 receptor agonists in type 2 diabetes

The use of overnight fasting copeptin and glucagon stimulated copeptin to diagnose arginine vasopressin deficiency in a tertiary centre

Copeptin concentrations increase during glucagon stimulation test: possible role of copeptin in assessment of anterior pituitary function

Bright and specific far-red labels for visualizing endogenous glucagon-like peptide-1 receptors

Glucagon like peptide-1 in congestive heart failure cases and type 2 diabetes mellitus cases

Comparison of the low dose synacthen and glucagon stimulation tests in the assessment of adrenal function in children with short stature

Removal of the dominantly secreting adrenal lateralized by bilateral adrenal venous sampling (BAVS) with glucagon stimulation significantly alleviated hypertension in patients with bilateral adrenal pheochromocytoma

An Ongoing Phase 2 Study of HM15136, a Novel Long-acting Glucagon Analogue, in Subjects with Congenital Hyperinsulinism (ACHIEVE, Outline Protocol)

10.17. Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and preclinical models of insulin-deficient diabetes

Effect of bariatric surgery on serum glucagon like peptide-1 concentration and metabolic parameters among obese type 2 diabetics

Glucagon like peptide-1 in congestive heart failure cases and type 2 diabetes mellitus cases

Comparison of GHRH + arginine vs glucagon test for the evaluation of growth hormone secretion status in a cohort of adults with Prader-Willi syndrome (PWS)

4.1. Accuracy of glucagon testing across transition in young adults with childhood-onset growth hormone deficiency

Glucagon-like-1 Receptor imaging specifically localizes insulinomas in patients with Multiple Endocrine Neoplasia Type 1 (MEN-1)

Effects of glucagon-like peptide-1 receptor agonists on bone blow flow and architecture in diabetic mice

Liraglutide, a glucagon-like peptide-1 receptor agonist, improves bone mass and architecture in ovariectomised mice

Increased Glucagon-Like Peptide-1 Response to Oral Glucose in Prepubertal Obese Children

Monitoring thyroid function in diabetic patients on treatment with glucagon-like peptide 1 analog

Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and reninangiotensinaldosterone system in healthy men

Glucagon-like peptide-1 stimulates insulin secretion and then somatostatin secretion in rat islets

Glucagon-like peptide-1 responses following multiple meals in lean and obese subjects

The comparison of combination test either with 1 μg acth test and glucagon test for the evaluation of hypothalamo-pituitary-adrenal axis in patients with pituitary disorders

Glucagon-like peptide-1 analogues: a new way to quit smoking? SKIP  a randomised controlled study

A comparison of glucagon stimulation and insulin tolerance test in young adults followed craniospinal irradiation

The role of Glucagon-Like Peptide 1 Receptor Agonists for Weight Control in Individuals with Acquired Hypothalamic Obesity- A Systematic Review

11.12. Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like peptide-1 receptor agonist

Audit of pituitary dysfunction after traumatic brain injury: caution in interpretation of glucagon stimulation test in diagnosis of GH and ACTH deficiency.

Could <sup>99m</sup>Tc labelled glucagon-like peptide 1 analogue scintigraphy be an answer for patients with persistent hypoglycaemia?

Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in polycystic ovary syndrome